People who have survived cancer as children are at higher risk of developing severe COVID-19, even decades after their diagnosis. This is shown by a new study from Karolinska Institutet published in the journal The Lancet Regional Health – Europe.

A recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating autophagy and MHC-I expression. The research, conducted by scientists from Chongqing Medical University, identifies XPR1 as a critical factor influencing the aggressiveness of ovarian cancer through its interaction with LAMP1 and the PI3K/Akt/mTOR signaling pathway. These findings shed light on new therapeutic targets for ovarian cancer, a malignancy known for its poor prognosis and resistance to immune checkpoint inhibitors.

The latest research published in Genes & Diseases unveils groundbreaking insights into the role of the aging process and the associated factor EMP1 in the progression of resectable pancreatic cancer (PC). The study, conducted by a team of researchers from the University of Chinese Academy of Sciences and Chongqing Medical University, has established a prognostic model that links EMP1 expression with adverse clinical outcomes, particularly among older PC patients.

Pathologists' examinations of tissue samples from skin cancer tumours improved when they were assisted by an AI tool. The assessments became more consistent and patients' prognoses were described more accurately. This is shown by a study led by Karolinska Institutet, conducted in collaboration with researchers from Yale University.

Using a novel tool they developed called BLOCK-ID, researchers at the University of Pittsburgh and Emory University have uncovered new details about how cancer cells repair their telomeres.

Insilico team employed advanced molecular modeling techniques in combination with the company’s proprietary generative AI-based chemistry engine, Chemistry42, to efficiently design highly selective FGFR2/3 inhibitors featuring a novel core structure. This research, recently published in the Journal of Medicinal Chemistry, provides an innovative approach for the discovery and development of next-generation cancer therapies targeting FGFR2/3.

Researchers have long focused on the STING (Stimulator of Interferon Genes) pathway as a way to harness the immune system’s natural defenses against cancer. This pathway, which plays a key role in helping the body defend against potential pathogens, can be leveraged to trigger an innate immune response that targets cancer cells. However, a study published July 3 in the journal Nature Chemical Biology, led by biochemist Lingyin Li (Bluesky: @lingyinli.bsky.social), is spearheading a new school of thought.